Cherrell Shells
Family Health · Flint, MINPI 1033410451
Payments from drug & device makers
Across 177 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$457
- AbbVie$423
- Otsuka America Pharmaceutical, Inc.$231
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$220
- Novo Nordisk$175
- Exact Sciences$148
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,721100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 22 | $457 |
| AbbVie | 52 | $423 |
| Otsuka America Pharmaceutical, Inc. | 13 | $231 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $220 |
| Novo Nordisk | 9 | $175 |
| Exact Sciences | 6 | $148 |
| Pfizer | 9 | $132 |
| E.r. Squibb & Sons, L.L.C. | 7 | $107 |
| Azurity Pharmaceuticals, Inc. | 6 | $105 |
| AstraZeneca | 6 | $97 |
| Lilly USA, LLC | 4 | $65 |
| Sanofi-aventis U.S. LLC | 2 | $56 |
| GSK | 3 | $55 |
| Axsome Therapeutics, Inc. | 3 | $55 |
| Amgen | 3 | $51 |
| Gilead | 3 | $41 |
| Lundbeck LLC | 2 | $35 |
| Novartis | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Boehringer Ingelheim | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Abbott | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Smith+Nephew | 1 | $15 |
| Inari Medical, Inc. | 1 | $14 |
How this compares
Too few family health providers in Michiganto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 73 | $87,215 |
| OzempicSemaglutide | 76 | $85,840 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $52,364 |
| JanuviaSitagliptin Phosphate | 53 | $48,132 |
| MounjaroTirzepatide | 32 | $31,791 |
| GemtesaVibegron | 41 | $20,832 |
| Atrovent HfaIpratropium Bromide | 28 | $15,295 |
| LinzessLinaclotide | 19 | $14,006 |
| TrintellixVortioxetine Hydrobromide | 16 | $13,782 |
| FarxigaDapagliflozin Propanediol | 22 | $12,322 |
| EliquisApixaban | 21 | $11,606 |
| EntrestoSacubitril/Valsartan | 12 | $11,511 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 307 | $10,083 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 534 | $8,390 |
| PremarinEstrogens, Conjugated | 25 | $7,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $65 | $119,007105 claims |
| Novo NordiskOzempic, Novolog | $175 | $87,30897 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $55 | $56,28790 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $33 | $20,83241 claims |
| AstraZenecaFarxiga, Symbicort | $97 | $19,40652 claims |
| PfizerEliquis, Premarin | $132 | $19,33946 claims |
| AbbVieLinzess | $423 | $14,00619 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $13,78216 claims |
| NovartisEntresto | $34 | $11,51112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in Michiganon file to place this against a meaningful peer group, so we don't.
Other family health in Flint
- Lisa FergusonCarson City$965
- Stephanie SharpeBrockway$489
- Dorothy LeeAlpena$158
- Shireen FradiHamtramck$85
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.